Original Publication Date: 24 December, 2013
Publication / Source: Breast Cancer Management
Authors: Della Makower, Lohith S Bachegowda & Joseph A Sparano
The taxanes, paclitaxel, docetaxel and nab-paclitaxel, are among the most active cytotoxic agents for treatment of breast cancer. Significant progress has been made in addressing taxane dose and schedule in both early-stage and metastatic disease. Several studies have clarified the role of retreatment with taxanes in recurrent breast cancer patients previously treated with taxane-containing regimens.